Lundbeck starts clinical development of potential new treatment of Parkinson’s disease

Lu AF28996 is the third compound added to Lundbeck’s clinical development pipeline in 2018.

H. Lundbeck A/S (Lundbeck) again expands its pipeline of clinical development projects with the initiation of a phase I study of a potential new treatment of Parkinson’s disease. The compound – Lu AF28996– is invented by Lundbeck and will now be studied in healthy volunteers as first part of its clinical development.


Lu AF28996 has the potential to treat common symptoms in patients with moderate/advanced Parkinson’s disease. Typically, patients gradually develop fluctuations in the control of their symptoms with poor or absent motor function (so called OFF episodes) and experience involuntary movements (dyskinesia). Both these symptoms are thought to be treated effectively with Lu AF28996.

It is a pleasure to bring another promising Lundbeck invention into clinical testing. This compound has the potential to significantly improve the lives of patients with Parkinson’s disease, many of whom today do not have effective treatment options. Hopefully we will be able to offer these patients much better symptom control in the future”, says Anders Gersel Pedersen, Executive Vice President, Research and Development at Lundbeck.

Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.